520 related articles for article (PubMed ID: 21262992)
1. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
[TBL] [Abstract][Full Text] [Related]
2. Letter by Hnid and Chtioui regarding article, "Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry".
Hnid K; Chtioui M
Circulation; 2011 Sep; 124(11):e297. PubMed ID: 21911791
[No Abstract] [Full Text] [Related]
3. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of response to clopidogrel and cardiovascular events.
Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
[TBL] [Abstract][Full Text] [Related]
5. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
6. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
[TBL] [Abstract][Full Text] [Related]
7. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
[TBL] [Abstract][Full Text] [Related]
10. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme.
Puymirat E; Lamhaut L; Bonnet N; Aissaoui N; Henry P; Cayla G; Cattan S; Steg G; Mock L; Ducrocq G; Goldstein P; Schiele F; Bonnefoy-Cudraz E; Simon T; Danchin N
Eur Heart J; 2016 Apr; 37(13):1063-71. PubMed ID: 26578201
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
[TBL] [Abstract][Full Text] [Related]
12. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Tran M; Tafreshi J; Pai RG
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
14. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
[TBL] [Abstract][Full Text] [Related]
16. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
[TBL] [Abstract][Full Text] [Related]
17. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB
Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Sorich MJ; Vitry A; Ward MB; Horowitz JD; McKinnon RA
J Thromb Haemost; 2010 Aug; 8(8):1678-84. PubMed ID: 20492467
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel and proton pump inhibitors--where do we stand in 2012?
Drepper MD; Spahr L; Frossard JL
World J Gastroenterol; 2012 May; 18(18):2161-71. PubMed ID: 22611308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
